Deamidation: difference between revisions
Diff·revision 11 → 12·19:03, 5 Mar 2025
Difference between revision 11 and revision 12 of Deamidation. 9 lines changed; the page grew by 666 bytes.
| Revision 11 — 17:46, 21 Feb 2025 ArchiveBot (talk) bot: repair redlinked category 3,531 bytes ±0 | Revision 12 — 19:03, 5 Mar 2025 ColumnOvenCoy (talk) add the equilibration time to the gradient description 4,197 bytes +666 | ||
|---|---|---|---|
| 26 | By mass spectrometry, the +0.984 Da shift requires high-resolution instrumentation to see on a peptide of a few kilodaltons. On a quadrupole instrument a deamidated peptide is indistinguishable from its parent, and a certificate reporting "observed mass matches calculated" from such an instrument has not excluded it.{{r|manning2010}} | 26 | By mass spectrometry, the +0.984 Da shift requires high-resolution instrumentation to see on a peptide of a few kilodaltons. On a quadrupole instrument a deamidated peptide is indistinguishable from its parent, and a certificate reporting "observed mass matches calculated" from such an instrument has not excluded it.{{r|manning2010}} |
| 27 | 27 | ||
| + | 28 | Because deamidation is slow at low temperature and in the solid state, it is largely a solution-phase problem. A [[Lyophilisation|lyophilised]] peptide stored cold deamidates very slowly; the same peptide in solution at ambient temperature can accumulate a measurable fraction over weeks. This is a principal reason for the [[Beyond-use date|beyond-use dating]] of reconstituted material.{{r|ich_q1a}} | |
| + | 29 | ||
| 28 | == References == | 30 | == References == |
| 29 | {{reflist}} | 31 | {{reflist}} |
| ⋮ | ⋮ | ||
| 31 | <ref name="manning2010">Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. "Stability of protein pharmaceuticals: an update." ''Pharmaceutical Research'' 27(4):544–575 (2010). PMID 20143256.</ref> | 33 | <ref name="manning2010">Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. "Stability of protein pharmaceuticals: an update." ''Pharmaceutical Research'' 27(4):544–575 (2010). PMID 20143256.</ref> |
| 32 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | 34 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> |
| + | 35 | <ref name="ich_q1a">International Council for Harmonisation, ''Q1A(R2): Stability Testing of New Drug Substances and Products'' (2003).</ref> | |
| + | 36 | ||
| + | 37 | == See also == | |
| + | 38 | * [[Methionine oxidation]] | |
| + | 39 | * [[Peptide aggregation]] | |
| + | 40 | * [[Mass spectrometry]] | |
| + | 41 | * [[Temperature excursion]] | |
| 33 | 42 | ||
| 34 | {{DEFAULTSORT:Deamidation}} | 43 | {{DEFAULTSORT:Deamidation}} |